

—Review—

The inflammatory process and successful implantation

Fumihisa Chishima*, Takahiro Nakajima, Takehiro Nakao, Chuyu Hayashi, Go Ichikawa, Atsushi Komatsu and Kei Kawana

Department of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo 173-8610, Japan

Abstract: Implantation is essential for successful reproduction. In humans, uterine receptivity is restricted to the mid-secretory phase, days 19 to 24 of the menstrual cycle; and this period is called the window of implantation (WOI). Large populations of decidual leukocytes infiltrate the implantation site, and the levels of cytokines, prostaglandins (PGs), and leukocytes are up-regulated in the endometrium during implantation. Implantation is like a local wound healing process which is characterized by a strong Th1, pro-inflammatory response in which high levels of pro-inflammatory cytokines such as IL-6, LIF, IL-8, and TNF α are involved. In addition, cyclooxygenase (COX)-2 expression increases between days 2 to 5, suggesting that PGs are necessary for the process of stromal cell decidualization in early pregnancy. Recently, it was reported that endometrial biopsies taken during spontaneous cycles that preceding IVF treatment improved the rate of implantation, clinical pregnancies, and live births in patients with recurrent implantation failure. These results suggest an inflammatory environment is not adequately induced in some IVF patients with recurrent implantation failure in the absence of local injury provoked by biopsy treatment, further suggesting that uterine receptivity is mediated by the expression of molecules associated with a pro-inflammatory process.

Key words: Implantation, Immune system, Inflammation

Introduction

Implantation and is necessary for successful reproduction occurs in a receptive uterus. In humans, uterine receptivity is restricted to the mid-secretory phase, days 19 to 24 of the menstrual cycle. This period of endometrial receptivity is called the window of implantation

(WOI). During WOI, fibroblast-like endometrial stromal cells transform into large rounded decidual cells [1], and large apical protrusions (pinopodes) and microvilli on the luminal epithelium appear [2]. Simultaneously, alterations in the expression of different cytokines, growth factors, transcription factors, prostaglandins, and adhesion molecules take place [3]. Imbalance in any of these protein levels may lead to pathological conditions and subsequent reproductive failures. On the other hand, the involvement of the immune system serves to provide protection from invading organisms, and this system appears to be crucial for successful implantation and maintenance of pregnancy [4]. This review discusses the inflammatory events in implantation and their roles in the reproductive system.

Implantation

The implantation process is divided into three steps; (1) apposition - initial contact of the blastocyst to the uterine wall; (2) adhesion - increased physical contact between the blastocyst and uterine epithelium; and (3) invasion - penetration and invasion of syncytiotrophoblast and cytotrophoblasts into the endometrium, inner third of the myometrium, and uterine vasculature. The levels of cytokines, prostaglandins, and leukocytes are up-regulated in the human endometrium during implantation [5]. Gradually increasing levels of chemokines and cytokines, produced by endometrial cells, guide the blastocyst to the implantation site allowing its interaction with the uterine lining. Trophoblast cells penetrate into the epithelial and stromal cells, during invasion. The endometrial tissue is repaired and remodeled by the growing placenta. In humans, this local wound healing-like process is characterized by a strong Th1, pro-inflammatory response in which high levels of pro-inflammatory cytokines such as IL-6, LIF, IL-8, and TNF α are involved [6, 7]. These cytokines and chemokines recruit immune cells to the decidua and

Table 1. Proportions of immune cells at the implantation site in early pregnancy

Immune cells	population (%)
Uterine specific natural killer cells	65–70
Macrophages } Dendritic cells }	antigen-presenting cells 10–20
Regulatory T cells	
NKT cells	
$\gamma\delta$ T cells	

large populations of human decidual leukocytes infiltrate the implantation site (Table 1). Among these recruited decidual leukocytes, 65–70% are uterine-specific natural killer (uNK) cells and 10–20% are antigen-presenting cells (APC) such as macrophages and dendritic cells [8]. Human decidual NK cells have been shown to play an important role in spiral artery remodeling and trophoblast invasion [9]. On the other hand, regulatory T cells have been shown to be important for fetus-specific immune tolerance in mice [10]. Decidual granular lymphocytes, called decidual NK cells, have been shown to exhibit a specific and distinct surface receptor repertoire allowing regulation by MHC class I molecules and non-MHC molecules that differ from those recognized by NK cells in the periphery [11]. Immune cells simultaneously exhibiting characteristics of NK cells and T cells, have been reported in the periphery and within the human endometrium and decidua [12, 13]. NKT cells have a phenotype suggesting they have an innate immune function and NKT cells at the implantation site are mediated by fetally expressed MHC class I or class I-like products derived from the paternal genome in mice [14]. Additionally, in mice, NKT cells secreting large amounts of interleukin (IL)-4 form the Th2-dominant milieu necessary for successful pregnancy [15].

Uterine dendritic cells (uDCs) are essential for decidual formation and may affect the angiogenic response by inhibiting blood vessel maturation in mice [16]. These cells form the initial contact with external antigens, controlling the antigen specific adaptive immune response. Macrophages are the second largest decidual leukocyte population in early pregnancy, and may be involved in implantation. They are natural candidates for contributing to tissue remodeling at the fetomaternal interface, given their pleiotropic functions in virtually all organ systems. Tissue remodeling involves transforming the spiral arterioles of the decidua into high-capacitance, low-resistance vessels and replacing the endothelium of these vessels with trophoblasts that have migrated from the placenta and invaded the decidua (they are termed extravillous

trophoblasts in humans, to distinguish them from the trophoblast subtypes that constitute the villous tree of the placenta proper) as well reviewed by Erlebacher [17]. Decidual macrophages exhibit a predominantly immunosuppressive phenotype, designated M2 polarization, that is characterized by increased IL-10 production and indoleamine 2,3-dioxygenase activity. Before embryo attachment, these decidual macrophages produce leukocyte factor and IL-1 β , which may help the endometrium become receptive to implantation by regulation of the surface glycan structure of epithelial cells in humans [18].

These noticeable roles of pathogen sensors and immune effector cells suggest they have a central role in the inflammatory responses to decidual or placental infection. As their function is elucidated, the biology of decidual macrophages represents an open area of research with major implications for human health.

Deletion of either macrophages, NK cells or dendritic cells (DC) has harmful effects in humans and mice [19–23]. In addition, Collins *et al.* demonstrated that uDC association with T cell responses to the fetal ‘allograft’ starkly contrast with their prominent role in organ transplant rejection in mice [24]. Dominant IL-10 and TGF- β mRNA expression has been observed in $\gamma\delta$ T cells of human early pregnancy decidua and that suggests they have an immune-regulatory potential [25]. These cells play an important role in changing the Th1, pro-inflammatory environment, into the Th2, anti-inflammatory environment during the later stages of pregnancy in human [26].

These findings give further support to the idea that the fetal–maternal immune interaction is more complex than that in transplant allograft. They suggest the presence of immune cells at the implantation site is not associated with a response to the ‘foreign’ fetus but to facilitate and protect the pregnancy. Moreover, the immune system at the implantation site is not suppressed. On the contrary, it is active, functional and carefully controlled the Th2 anti-inflammatory response starting after implantation having a critical role in the continuation of pregnancy.

Endometrial Th1 Inflammatory Response and Successful Implantation

The remodeling of the female reproductive tract after menstruation is similar to that of injured tissue repair, involving inflammatory activity balanced with vascular, connective tissue, and epithelial cell remodeling in humans [27]. In guinea-pigs, injury induced by scratching of the progesterational uterus provokes a rapid growth of endometrial cells, which are identical to the decidual cells

of pregnancy [28]. In rat model, decidualization in the progesterone uterus was induced by trauma, such as the intrauterine injection of oil [29]. These observations suggest there is a positive association between uterine mechanical manipulation and pregnancy outcome in human patients. It has been reported that endometrial biopsies taken during the spontaneous cycles that precede the IVF treatment more than doubled the rate of implantation, clinical pregnancies, and live births [30, 31]. These studies demonstrate the beneficial effect of local endometrial injury on IVF success. Unfortunately, there is no evidence based on a controlled clinical study with a large sample size that endometrial biopsy increases the implantation rate in IVF patients. Nevertheless, endometrial biopsy may have the potential to increase the implantation rate in IVF patients.

Prior biopsy treatment in the proliferative phase induced the production of larger amounts of macrophages/dendritic cells, and elevated inflammatory cytokines, tumor necrosis factor- α (TNF- α), growth regulated oncogene- α (GRO- α), interleukin-15 (IL-15), macrophage inflammatory protein 1B (MIP-1B), and osteopontin (OPN). A positive correlation was observed between the level of macrophages/dendritic cells, MIP-1B, expression, and TNF- α expression and the pregnancy outcome in humans [32]. A biopsy-induced inflammatory response may facilitate the preparation of the endometrium for implantation. Macrophages and dendritic cells which are present in human endometrium have been shown to play a role in decidualization and implantation. Elevated amounts of macrophages and dendritic cells after biopsy treatment may be recruited by MIP-1B and GRO- α , or be differentiated from the monocytes that were stimulated to migrate to the site of injury by these cytokines. Macrophages and dendritic cells have the potential to secrete many cytokines/chemokines and enzymes that are related to tissue remodeling and angiogenesis [33, 34]. These secreted chemicals may act as mediators of immune cells that potentially target the luminal epithelium, thus contributing to the acquisition of endometrial receptivity in humans [7]. On the basis of these findings, local injury induced by endometrial biopsy seems to promote inflammatory responses. Pro-inflammatory cytokines such as TNF- α , produced by the wounded endometrium, increase the secretion of other cytokines/chemokines which, in turn, recruit macrophages and dendritic cells to the site of implantation in humans [35]. The local environment at the implantation site may be pro-inflammatory in humans, but the inflammatory milieu may not be adequately induced in some IVF patients with recurrent implantation failure in the absence of local injury provoked by the biopsy treat-

ment, and this may explain the beneficial effects of endometrial injury on implantation and pregnancy success in patients undergoing assisted reproductive technology [36]. Accordingly, it is considered that uterine receptivity is mediated by the expression of molecules associated with inflammation.

Thrombotic/inflammatory processes are often observed at the maternal-fetal interface as the final pathological event in many cases of recurrent pregnancy loss (RPL). Both inherited and acquired thrombophilic conditions have been reported to be associated with RPL [37]. Thrombophilia and cellular immune abnormalities were present in more than half of recurrent pregnancy loss cases (72.4% and 63.3%, respectively), and in both known and unknown etiologies of RPL with comparable prevalence. The type 1 inflammatory immune response enhances the coagulation pathways, and the presence of inherited or acquired thrombophilia accentuates inflammation-induced thrombotic pathology at the maternal-fetal interface. Treatment based on a thorough evaluation of the underlying etiology including cellular immunity and thrombophilia may lead to a significantly improved live birth rate in women with RPL [38] (Fig. 1).

The Role of Prostaglandins at the Site of Implantation

Prostaglandins are produced from arachidonic acid which is released from the membrane phospholipids by phospholipase A2 enzyme in rats [39]. Arachidonic acid is converted into PGH₂ by PG-endoperoxide synthase (PTGS), also known as cyclooxygenase (COX). There are two isoforms of COX. One is the constitutively expressed enzyme (COX-1), and the other is the inducible enzyme (COX-2) [40]. PGH₂ is rapidly converted into various other prostanoids by specific terminal PG synthases. The latter include PGE synthase (PGES), PGIS, PGDS, PGFS, and thromboxane synthase (TXS) that forms PGE₂, PGI₂, PGD₂, PGF₂ α , and TXA₂ from PGH₂.

After blastocyst attachment, vascular permeability increases and stromal edema appears in rats [41]. Alterations in vascular permeability are followed by a progressive increase in angiogenesis in mice [42]. These changes in vascular permeability and angiogenesis at the time of implantation are induced by differential expression of proangiogenic factor in the uterus, as well as vascular endothelial growth factor (VEGF) and its receptor in rats [43]. VEGF accompanied with angiopoietin (Ang)-1, and Ang-2 induce angiogenesis during decidualization.

PGs and platelet-activating factor (PAF) are important paracrine factors involved in the increase in vascular per-




Fig. 1 The endometrial Th1 inflammatory response; TNF- α , tumor necrosis factor- α ; GRO- α , growth-regulated oncogene- α ; IL15, Interleukin-15; MIP-1B, macrophage inflammatory protein 1B; PGs, prostaglandins; VEGF, vascular endothelial growth factor; Ang-1, -2, angiopoietin-1, -2

meability at the site of embryo implantation in humans [44]. Interaction between PAF and its receptor results in a rapid release of nitric oxide (NO), a potent vasodilator, increases VEGF expression, and activates focal adhesion kinase, FAKpp125 in humans [45]. PGE₂ is more effective than prostacyclin (PGI₂), PPAR- γ , and retinoic acid (RXRA) at increasing in endometrial vascular permeability in rats [46]. PGE₂ mediates sex-steroid effects on VEGF and angiopoietin expression leading to increases in vascular permeability and angiogenesis during implantation. In the rat, the activity of nitric oxide synthase (NOS), an enzyme responsible for NO production, which was reported to be highest at embryo implantation [47], was inhibited by PGE₂ [48]. PGE₂ could be involved in the control of the extent of vascular permeability induced by NO, since PGF₂ α was found to cause an acute increase in blood flow to the corpus luteum by stimulating the activity of epithelial nitric oxide synthase (eNOS) in bovine [49].

Prostacyclin (PGI₂) is a potent vasodilator, and has been reported to play a role in the increase in vascular permeability at the implantation site. Prostacyclin binds to IP in glandular epithelial cells, resulting in rapid activation of extracellular signal-regulated kinase (ERK) 1/2 as well as inducing the expression of proangiogenic genes, basic fibroblast growth factor (bFGF), and Ang-1 and Ang-2, via cross talk with the epidermal growth factor receptor (EGF-R) in humans [50].

Decidual cells have been reported to synthesize and secrete PGs and express PG receptors in humans [51, 52]. Upregulation of COX-1, COX-2, cPGES, and mPGES expression in humans [53, 54], and upregulation of AKR1B1, a highly functioning PGF synthase responsible for PGF₂a production, all indicate an increase in PG synthesis [55]. In addition, COX-2 expression increases between days 2 to 5, suggesting that PGs are necessary for the process of stromal cell decidualization in early pregnancy in rats [56]. The increase in the expression of EP2 and PPAR- γ in mouse decidual cells means PGs are involved in implantation in mice [57]. The involvement of PGs in progesterone-induced decidualization has been reported. COX-2 was reported to regulate the expression of Snail transcription repressor in mice [58]. Dysregulation of EGF and COX-2 expression in the mouse uteri during the peri-implantation period, which is associated with a high plasma progesterone level resulted in implantation failure [59].

Concluding Remarks

PGs have been reported to play roles in the increase in vascular permeability, stromal decidualization, blastocyst growth and development, leukocyte recruitment, trophoblast invasion, and extracellular matrix remodeling during implantation. Inappropriate levels of PG synthases will lead to implantation failure. Embryo implantation is

associated with an active Th1 inflammatory response, while Th2-humoral inflammation is required for pregnancy maintenance. Local injury induced by endometrial biopsy may improve uterine receptivity by eliciting an inflammatory reaction in patients with recurrent implantation failure. Thus, successful implantation may well be a controlled inflammatory process.

References

- 1) Dunn, C.L., Kelly, R.W. and Critchley, H.O. (2003): Decidualization of the human endometrial stromal cell: an enigmatic transformation. *Reprod. Biomed. Online*, 7, 151–161. [[Medline](#)] [[CrossRef](#)]
- 2) Paria, B.C., Reese, J., Das, S.K. and Dey, S.K. (2002): Deciphering the cross-talk of implantation: advances and challenges. *Science*, 296, 2185–2188. [[Medline](#)] [[CrossRef](#)]
- 3) Wang, H. and Dey, S.K. (2006): Roadmap to embryo implantation: clues from mouse models. *Nat. Rev. Genet.*, 7, 185–199. [[Medline](#)] [[CrossRef](#)]
- 4) Mor, G., Cardenas, I., Abrahams, V. and Guller, S. (2011): Inflammation and pregnancy: the role of the immune system at the implantation site. *Ann. N. Y. Acad. Sci.*, 1221, 80–87. [[Medline](#)] [[CrossRef](#)]
- 5) Kelly, R.W., King, A.E. and Critchley, H.O. (2001): Cytokine control in human endometrium. *Reproduction*, 121, 3–19. [[Medline](#)] [[CrossRef](#)]
- 6) Dominguez, F., Yáñez-Mó, M., Sanchez-Madrid, F. and Simón, C. (2005): Embryonic implantation and leukocyte transendothelial migration: different processes with similar players? *FASEB J.*, 19, 1056–1060. [[Medline](#)] [[CrossRef](#)]
- 7) van Mourik, M.S., Macklon, N.S. and Heijnen, C.J. (2009): Embryonic implantation: cytokines, adhesion molecules, and immune cells in establishing an implantation environment. *J. Leukoc. Biol.*, 85, 4–19. [[Medline](#)] [[CrossRef](#)]
- 8) Hanna, J., Goldman-Wohl, D., Hamani, Y., Avraham, I., Greenfield, C., Natanson-Yaron, S., Prus, D., Cohen-Daniel, L., Arnon, T.I., Manaster, I., Gazit, R., Yutkin, V., Benharroch, D., Porgador, A., Keshet, E., Yagel, S. and Mandelboim, O. (2006): Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. *Nat. Med.*, 12, 1065–1074. [[Medline](#)] [[CrossRef](#)]
- 9) Smith, S.D., Dunk, C.E., Aplin, J.D., Harris, L.K. and Jones, R.L. (2009): Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy. *Am. J. Pathol.*, 174, 1959–1971. [[Medline](#)] [[CrossRef](#)]
- 10) Darrasse-Jèze, G., Klatzmann, D., Charlotte, F., Salomon, B.L. and Cohen, J.L. (2006): CD4+CD25+ regulatory/suppressor T cells prevent allogeneic fetus rejection in mice. *Immunol. Lett.*, 102, 106–109. [[Medline](#)] [[CrossRef](#)]
- 11) Godfrey, D.I., Hammond, K.J., Poulton, L.D., Smyth, M.J. and Baxter, A.G. (2000): NKT cells: facts, functions and fallacies. *Immunol. Today*, 21, 573–583. [[Medline](#)] [[CrossRef](#)]
- 12) Boyson, J.E., Rybalov, B., Koopman, L.A., Exley, M., Balk, S.P., Racke, F.K., Schatz, F., Masch, R., Wilson, S.B. and Strominger, J.L. (2002): CD1d and invariant NKT cells at the human maternal-fetal interface. *Proc. Natl. Acad. Sci. USA*, 99, 13741–13746. [[Medline](#)] [[CrossRef](#)]
- 13) Male, V., Trundley, A., Gardner, L., Northfield, J., Chang, C., Apps, R. and Moffett, A. (2010): Natural killer cells in human pregnancy. *Methods Mol. Biol.*, 612, 447–463. [[Medline](#)] [[CrossRef](#)]
- 14) Dang, Y. and Heyborne, K.D. (2001): Cutting edge: regulation of uterine NKT cells by a fetal class I molecule other than CD1. *J. Immunol.*, 166, 3641–3644. [[Medline](#)] [[CrossRef](#)]
- 15) Dang, Y., Beckers, J., Wang, C.R. and Heyborne, K.D. (2000): Natural killer 1.1(+) $\alpha\beta$ T cells in the periimplantation uterus. *Immunology*, 101, 484–491. [[Medline](#)]
- 16) Plaks, V., Birnberg, T., Berkutzki, T., Sela, S., BenYashar, A., Kalchenko, V., Mor, G., Keshet, E., Dekel, N., Neeman, M. and Jung, S. (2008): Uterine DCs are crucial for decidua formation during embryo implantation in mice. *J. Clin. Invest.*, 118, 3954–3965. [[Medline](#)]
- 17) Erlebacher, A. (2013): Immunology of the maternal-fetal interface. *Annu. Rev. Immunol.*, 31, 387–411. [[Medline](#)] [[CrossRef](#)]
- 18) Nakamura, H., Jasper, M.J., Hull, M.L., Aplin, J.D. and Robertson, S.A. (2012): Macrophages regulate expression of α 1,2-fucosyltransferase genes in human endometrial epithelial cells. *Mol. Hum. Reprod.*, 18, 204–215. [[Medline](#)] [[CrossRef](#)]
- 19) Greenwood, J.D., Minhas, K., di Santo, J.P., Makita, M., Kiso, Y. and Croy, B.A. (2000): Ultrastructural studies of implantation sites from mice deficient in uterine natural killer cells. *Placenta*, 21, 693–702. [[Medline](#)] [[CrossRef](#)]
- 20) Abrahams, V.M., Kim, Y.M., Straszewski, S.L., Romero, R. and Mor, G. (2004): Macrophages and apoptotic cell clearance during pregnancy. *Am. J. Reprod. Immunol.*, 51, 275–282. [[Medline](#)] [[CrossRef](#)]
- 21) Le Bouteiller, P., and Piccinni, M.P. (2008): Human NK cells in pregnant uterus: why there? *Am. J. Reprod. Immunol.*, 59, 401–406. [[Medline](#)] [[CrossRef](#)]
- 22) Manaseki, S., and Searle, R.F. (1989): Natural killer (NK) cell activity of first trimester human decidua. *Cell. Immunol.*, 121, 166–173. [[Medline](#)] [[CrossRef](#)]
- 23) Blois, S.M., Iñarregui, J.M., Tometten, M., Garcia, M., Orsal, A.S., Cordo-Russo, R., Toscano, M.A., Bianco, G.A., Kobelt, P., Handjiski, B., Tirado, I., Markert, U.R., Klapp, B.F., Poirier, F., Szekeres-Bartho, J., Rabinovich, G.A. and Arck, P.C. (2007): A pivotal role for galectin-1 in fetomaternal tolerance. *Nat. Med.*, 13, 1450–1457. [[Medline](#)] [[CrossRef](#)]
- 24) Collins, M.K., Tay, C.S. and Erlebacher, A. (2009): Dendritic cell entrapment within the pregnant uterus inhibits immune surveillance of the maternal/fetal interface in mice. *J. Clin. Invest.*, 119, 2062–2073. [[Medline](#)]
- 25) Nagaeva, O., Jonsson, L. and Mincheva-Nilsson, L. (2002): Dominant IL-10 and TGF- β mRNA expression in gamma-delta T cells of human early pregnancy decidua suggests immunoregulatory potential. *Am. J. Reprod. Immunol.*, 48, 9–17. [[Medline](#)] [[CrossRef](#)]
- 26) Nagamatsu, T. and Schust, D.J. (2010): The contribution of macrophages to normal and pathological pregnancies. *Am.*

- J. *Reprod. Immunol.*, 63, 460–471. [[Medline](#)] [[CrossRef](#)]
- 27) Ruszczak, Z. and Schwartz, R.A. (2000): Modern aspects of wound healing: An update. *Dermatol. Surg.*, 26, 219–229. [[Medline](#)] [[CrossRef](#)]
 - 28) Loeb, L. (1907): Ueber die experimentelle Erzeugung von Knoten von Deciduagewebe in dem Uterus des Meerschweinchens nach stattgefundenen copulation. *Zentralbl. Allg. Pathol.*, 18, 563–565.
 - 29) Turner, C.D. and Bagnara, J.T. (1976): Biological effects of the ovarian hormones. In *General Endocrinology*, pp 466–476, 6th Edn. Philadelphia, PA, USA: Saunders.
 - 30) Barash, A., Dekel, N., Fieldust, S., Segal, I., Schechtman, E. and Granot, I. (2003): Local injury to the endometrium doubles the incidence of successful pregnancies in patients undergoing in vitro fertilization. *Fertil. Steril.*, 79, 1317–1322. [[Medline](#)] [[CrossRef](#)]
 - 31) Razieli, A., Schachter, M., Strassburger, D., Bern, O., Ron-El, R. and Friedler, S. (2007): Favorable influence of local injury to the endometrium in intracytoplasmic sperm injection patients with high-order implantation failure. *Fertil. Steril.*, 87, 198–201. [[Medline](#)] [[CrossRef](#)]
 - 32) Gnainsky, Y., Granot, I., Aldo, P.B., Barash, A., Or, Y., Schechtman, E., Mor, G. and Dekel, N. (2010): Local injury of the endometrium induces an inflammatory response that promotes successful implantation. *Fertil. Steril.*, 94, 2030–2036. [[Medline](#)] [[CrossRef](#)]
 - 33) David Dong, Z.M., Aplin, A.C. and Nicosia, R.F. (2009): Regulation of angiogenesis by macrophages, dendritic cells, and circulating myelomonocytic cells. *Curr. Pharm. Des.*, 15, 365–379. [[Medline](#)] [[CrossRef](#)]
 - 34) Goetzl, E.J., Banda, M.J. and Leppert, D. (1996): Matrix metalloproteinases in immunity. *J. Immunol.*, 156, 1–4. [[Medline](#)]
 - 35) Dekel, N., Gnainsky, Y., Granot, I., Racicot, K. and Mor, G. (2014): The role of inflammation for a successful implantation. *Am. J. Reprod. Immunol.*, 72, 141–147. [[Medline](#)] [[CrossRef](#)]
 - 36) Gnainsky, Y., Granot, I., Aldo, P., Barash, A., Or, Y., Mor, G. and Dekel, N. (2015): Biopsy-induced inflammatory conditions improve endometrial receptivity: the mechanism of action. *Reproduction*, 149, 75–85. [[Medline](#)] [[CrossRef](#)]
 - 37) Kwak-Kim, J., Yang, K.M. and Gilman-Sachs, A. (2009): Recurrent pregnancy loss: a disease of inflammation and coagulation. *J. Obstet. Gynaecol. Res.*, 35, 609–622. [[Medline](#)] [[CrossRef](#)]
 - 38) Lee, S.K., Kim, J.Y., Han, A.R., Hur, S.E., Kim, C.J., Kim, T.H., Cho, B.R., Han, J.W., Han, S.G., Na, B.J. and Kwak-Kim, J. (2016): Intravenous Immunoglobulin G Improves Pregnancy Outcome in Women with Recurrent Pregnancy Losses with Cellular Immune Abnormalities. *Am. J. Reprod. Immunol.*, 75, 59–68. [[Medline](#)] [[CrossRef](#)]
 - 39) Satoh, H., Watanabe, K., Kawaminami, M. and Kurusu, S. (2013): A comprehensive immunohistochemistry of prostaglandins F2 α and E2 synthetic enzymes in rat ovary and uterus around parturition. *Prostaglandins Other Lipid Mediat.*, 106, 23–28. [[Medline](#)] [[CrossRef](#)]
 - 40) Herschman, H.R. (1996): Prostaglandin synthase 2. *Biochim. Biophys. Acta*, 1299, 125–140. [[Medline](#)] [[CrossRef](#)]
 - 41) Beltrame, J.S., Sordelli, M.S., Cella, M., Perez Martinez, S., Franchi, A.M. and Ribeiro, M.L. (2013): Lysophosphatidic acid increases the production of pivotal mediators of decidualization and vascularization in the rat uterus. *Placenta*, 34, 751–756. [[Medline](#)] [[CrossRef](#)]
 - 42) Plaks, V., Kalchenko, V., Dekel, N. and Neeman, M. (2006): MRI analysis of angiogenesis during mouse embryo implantation. *Magn. Reson. Med.*, 55, 1013–1022. [[Medline](#)] [[CrossRef](#)]
 - 43) Rabbani, M.L. and Rogers, P.A. (2001): Role of vascular endothelial growth factor in endometrial vascular events before implantation in rats. *Reproduction*, 122, 85–90. [[Medline](#)] [[CrossRef](#)]
 - 44) Ahmed, A., Dearn, S., Shams, M., Li, X.F., Sangha, R.K., Rola-Pleszczynski, M. and Jiang, J. (1998): Localization, quantification, and activation of platelet-activating factor receptor in human endometrium during the menstrual cycle: PAF stimulates NO, VEGF, and FAKp125. *FASEB J.*, 12, 831–843. [[Medline](#)]
 - 45) Soldi, R., Sanavio, F., Aglietta, M., Primo, L., Defilippi, P., Marchisio, P.C. and Bussolino, F. (1996): Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125FAK) in human endothelial cells. *Oncogene*, 13, 515–525. [[Medline](#)]
 - 46) Gillio-Meina, C., Phang, S.H., Mather, J.P., Knight, B.S. and Kennedy, T.G. (2009): Expression patterns and role of prostaglandin-endoperoxide synthases, prostaglandin E synthases, prostacyclin synthase, prostacyclin receptor, peroxisome proliferator-activated receptor delta and retinoid x receptor alpha in rat endometrium during artificially-induced decidualization. *Reproduction*, 137, 537–552. [[Medline](#)] [[CrossRef](#)]
 - 47) Sordelli, M.S., Beltrame, J.S., Burdet, J., Zotta, E., Pardo, R., Cella, M., Franchi, A.M. and Ribeiro, M.L. (2011): The effect of anandamide on uterine nitric oxide synthase activity depends on the presence of the blastocyst. *PLoS One*, 6, e18368. [[Medline](#)] [[CrossRef](#)]
 - 48) Cella, M., Aisemberg, J., Sordelli, M.S., Billi, S., Farina, M., Franchi, A.M. and Ribeiro, M.L. (2006): Prostaglandins modulate nitric oxide synthase activity early in time in the uterus of estrogenized rat challenged with lipopolysaccharide. *Eur. J. Pharmacol.*, 534, 218–226. [[Medline](#)] [[CrossRef](#)]
 - 49) Shirasuna, K., Watanabe, S., Asahi, T., Wijayagunawardane, M.P., Sasahara, K., Jiang, C., Matsui, M., Sasaki, M., Shimizu, T., Davis, J.S. and Miyamoto, A. (2008): Prostaglandin F2 α increases endothelial nitric oxide synthase in the periphery of the bovine corpus luteum: the possible regulation of blood flow at an early stage of luteolysis. *Reproduction*, 135, 527–539. [[Medline](#)] [[CrossRef](#)]
 - 50) Smith, O.P., Battersby, S., Sales, K.J., Critchley, H.O. and Jabbour, H.N. (2006): Prostacyclin receptor up-regulates the expression of angiogenic genes in human endometrium via cross talk with epidermal growth factor Receptor and the extracellular signaling receptor kinase 1/2 pathway. *Endocrinology*, 147, 1697–1705. [[Medline](#)] [[CrossRef](#)]
 - 51) Kang, J., Chapdelaine, P., Laberge, P.Y. and Fortier, M.A. (2006): Functional characterization of prostaglandin trans-

- porter and terminal prostaglandin synthases during decidualization of human endometrial stromal cells. *Hum. Reprod.*, 21, 592–599. [[Medline](#)] [[CrossRef](#)]
- 52) Arosh, J.A., Banu, S.K., Chapdelaine, P., Emond, V., Kim, J.J., MacLaren, L.A. and Fortier, M.A. (2003): Molecular cloning and characterization of bovine prostaglandin E2 receptors EP2 and EP4: expression and regulation in endometrium and myometrium during the estrous cycle and early pregnancy. *Endocrinology*, 144, 3076–3091. [[Medline](#)] [[CrossRef](#)]
- 53) Shaw, K.J., Ng, C. and Kovacs, B.W. (1994): Cyclooxygenase gene expression in human endometrium and decidua. *Prostaglandins Leukot. Essent. Fatty Acids*, 50, 239–243. [[Medline](#)] [[CrossRef](#)]
- 54) Alfaidy, N., Sun, M., Challis, J.R. and Gibb, W. (2003): Expression of membrane prostaglandin E synthase in human placenta and fetal membranes and effect of labor. *Endocrine*, 20, 219–225. [[Medline](#)] [[CrossRef](#)]
- 55) Bresson, E., Boucher-Kovalik, S., Chapdelaine, P., Madore, E., Harvey, N., Laberge, P.Y., Leboeuf, M. and Fortier, M.A. (2011): The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium. *J. Clin. Endocrinol. Metab.*, 96, 210–219. [[Medline](#)] [[CrossRef](#)]
- 56) St-Louis, I., Singh, M., Brasseur, K., Leblanc, V., Parent, S. and Asselin, E. (2010): Expression of COX-1 and COX-2 in the endometrium of cyclic, pregnant and in a model of pseudopregnant rats and their regulation by sex steroids. *Reprod. Biol. Endocrinol.*, 8, 103. [[Medline](#)] [[CrossRef](#)]
- 57) Pakrasi, P.L. and Jain, A.K. (2008): Cyclooxygenase-2 derived PGE2 and PGI2 play an important role via EP2 and PPARdelta receptors in early steps of oil induced decidualization in mice. *Placenta*, 29, 523–530. [[Medline](#)] [[CrossRef](#)]
- 58) Zhang, X.H., Liang, X., Wang, T.S., Liang, X.H., Zuo, R.J., Deng, W.B., Zhang, Z.R., Qin, F.N., Zhao, Z.A. and Yang, Z.M. (2013): Heparin-binding epidermal growth factor-like growth factor (HB-EGF) induction on Snail expression during mouse decidualization. *Mol. Cell. Endocrinol.*, 381, 272–279. [[Medline](#)] [[CrossRef](#)]
- 59) Song, H., Lim, H., Das, S.K., Paria, B.C. and Dey, S.K. (2000): Dysregulation of EGF family of growth factors and COX-2 in the uterus during the preattachment and attachment reactions of the blastocyst with the luminal epithelium correlates with implantation failure in LIF-deficient mice. *Mol. Endocrinol.*, 14, 1147–1161. [[Medline](#)] [[CrossRef](#)]